RESUMEN
BACKGROUND: Direct-acting antiviral (DAA) regimens have shown high efficacy and tolerability for patients with HCV genotype 1/1b (GT1/1b) in clinical trials. However, robust real-world evidence of interferon (IFN)-free DAA treatment for HCV GT1-infected patients in Asia is still lacking. AIM: To systematically review and meta-analyse the effectiveness and tolerability of IFN-free DAA therapy for HCV GT1 infection in Asia. METHODS: We included studies that enrolled adult patients with HCV GT1 infection in routine clinical practice in Asia, using IFN-free DAA regimens, and reported sustained virological response (SVR) after 12/24 weeks end-of-treatment by 31 May 2017. The pooled SVR rates were computed with a random-effects model. Subgroup analysis and meta-regression as previously registered in PROSPERO were performed to determine how pre-planned variables might have affected the pooled estimates. RESULTS: We included 41 studies from eight countries and regions, comprising of 8574 individuals. The pooled SVR rates for GT1 were 89.9% (95% CI 88.6-91.1, I2 = 55.1%) with daclatasvir/asunaprevir (DCV/ASV) and 98.1% (95% CI 97.0-99.0, I2 = 41.0%) with ledipasvir/sofosbuvir ± ribavirin (LDV/SOF ± RBV). Baseline cirrhosis but not prior treatment history and age, attenuated the effectiveness of both regimens. Baseline resistance associated substitutions (RASs) severely attenuated SVR of DCV/ASV (65.4% vs 94.3%, P < 0.001) and only minimally with LDV/SOF ± RBV (94.5% vs 99.2%, P = 0.003). Patients with renal dysfunction treated with DCV/ASV showed a higher SVR rate (93.9% vs 89.8%, P = 0.046). Patients with hepatocellular carcinoma (HCC) LDV/SOF ± RBV achieved a lower SVR than those without HCC (94.1% vs 98.7%, P = 0.001). CONCLUSION: All oral DAA treatment of HCV GT1 resulted in high cure rates in Asian patients in routine clinical practice setting including elderly patients and those with end-stage renal disease.
Asunto(s)
Antivirales/uso terapéutico , Hepacivirus/efectos de los fármacos , Hepacivirus/genética , Hepatitis C Crónica/tratamiento farmacológico , Adulto , Asia/epidemiología , Quimioterapia Combinada/efectos adversos , Medicina General/estadística & datos numéricos , Genotipo , Hepatitis C Crónica/epidemiología , Hepatitis C Crónica/virología , Humanos , Resultado del TratamientoRESUMEN
Over the past several years, thousands of networked information resources have become available to individuals and institutions with access to the Internet. Unfortunately, the dizzying array of computing and networking environments often frustrates end users' attempts to navigate the Internet. Librarians have begun to take responsibility not only for instructing users in the use of basic network tools such as file transfer, remote log-in, and electronic mail, but also for answering questions concerning network access and even information system design. The authors show how, by continuing to adapt to this new and volatile environment, health sciences librarians find themselves playing increasingly important roles in shaping the information policies and practices of their institutions. To illustrate these new roles, the authors review the experiences of health sciences librarians at the University of California, Los Angeles, and the University of California, San Diego. These institutions have varying and complex networking environments, and their biomedical libraries have taken lead roles in clarifying and interpreting their particular Internet features.